What is Tachyphylaxis?
Tachyphylaxis is the rapid development of drug tolerance characterized by a progressive decrease in response to a given dose after repetitive administration of a pharmacologically active substance 1, 2.
Mechanistic Definition
The phenomenon should be mechanistically distinguished from tolerance based on the underlying cellular process 2:
- Tachyphylaxis occurs specifically due to cellular depletion (e.g., depletion of neurotransmitter stores or receptor availability)
- Tolerance arises from cellular adaptations (e.g., receptor downregulation, desensitization mechanisms)
This distinction has practical implications for managing or preventing the attenuation of drug response with repeated administration 2.
Clinical Characteristics
Timing and Onset
- Develops rapidly after administration of only a few doses 3
- Can occur within minutes to hours of repeated exposure
- Represents an acute loss of functional receptor response after repeated stimuli 4
Key Mechanism: Ligand Residence Time
Recent evidence demonstrates that longer receptor residence time of agonists leads to more sustained receptor activation, increased internalization, and delayed receptor recycling to the plasma membrane, thereby preventing further receptor responses and manifesting as tachyphylaxis 4. Conversely, drugs with shorter receptor residence times exhibit reduced tachyphylaxis.
Drugs Commonly Associated with Tachyphylaxis
Based on pharmacovigilance data from over 29 million adverse event reports 1:
- Corticosteroids
- Opioids
- Antihistamines
- Nitroglycerin
- Sympathomimetics
- Antineoplastics
- Immunosuppressants
- Psychoactive drugs (psycholeptics and psychoanaleptics)
- Anesthetics (propofol, cisatracurium)
- Antidepressants (may occur in up to 33% of patients) 5
Clinical Significance
Morbidity and Mortality Impact
Among reported cases of tachyphylaxis 1:
- 16.9% required hospitalization
- 5% resulted in disability
- 2.5% resulted in death
Important Clinical Caveat
The perception of tachyphylaxis may exceed its actual occurrence in clinical practice. For example, in a 12-week prospective study of topical corticosteroids in psoriasis, despite 57% of dermatologists believing tachyphylaxis occurs after 8 weeks, zero of 32 patients exhibited detectable signs of tachyphylaxis 3. What clinicians perceive as tachyphylaxis may actually represent:
- Therapeutic limitations of the drug
- Compliance issues
- Disease flares unrelated to therapy
- Inadequate initial dosing
Relationship to Desensitization
Tachyphylaxis can be understood as a form of slow desensitization that is partially reversible 6. The process occurs when receptors remain in the open/activated state, leading to progressive functional impairment with repeated activations.